|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin highlights the services many of these outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes.
|
|
|
Ronald Aung-Din, MD, and Chantelle G. Martin, MBChB, present scientific data demonstrating how with NeuroDirect technology, the benefits of psychedelic compounds may be achieved without concern for their potential systemic effects.
|
|
|
Tim Clackson, PhD, says the goal in targeted oncology is to achieve pan-variant inhibition and, ideally, pan-variant inhibition should be accomplished with a single agent, avoiding the potential complications and toxicities of drug combinations.
|
|
|
Suhas Gudihal, MS, MBA, explains how the COVID-19 pandemic has accelerated the ongoing shift to remote clinical trial monitoring, and remote site access and monitoring platforms are now an essential element of the clinical trial process and a vital connection between the sponsor, CRO, and research site.
|
|
|
|
|
|
|
|
|

Fortis Life Sciences offers world-class reagents, tools, materials, and custom services with a best-in-class customer experience for our customers in the biopharma industry. Through our brand nanoComposix, we provide precisely engineered and highly characterized nanomaterials to a global customer base. nanoComposix is an ISO 13485 (2016)-Certified*, FDA-registered developer and contract manufacturer with a nanomaterial product portfolio containing hundreds of variants engineered to address the unique challenges presented by our customers. Our products and CDMO services are backed by technical teams with extensive expertise in nanotechnology, biology, chemistry, physics, and optics. Click here for more.
|
|
|
|
|
|
 |
|
Hovione and Ripple Therapeutics have entered a strategic partnership to expand the use of Ripple’s Epidel® platform beyond ophthalmic applications….
|
|
 |
|
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, recently announced it has entered into a Research Agreement with Bicycle Therapeutics plc, a biotechnology company pioneering a new….
|
|
 |
|
Pfizer Inc. and Seagen Inc. recently announced they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash….
|
|
 |
|
This strategic alliance will give a unique advantage to pharmaceutical & bio-tech customers – accelerating the go-to-market of their drug-device combination products by offering analytical chemistry, drug compatibility lab testing and expert advice….
|
|
|
|
|
|
|
|
 |
|
Join us to hear about our new biotherapeutic antibody discovery service — the Pioneer Platform, and how it can help you find your next lead candidate.
|
|
|
|
|
|
|
|
 |
|
This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.
Click here to …
|
|
 |
|
By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*
Summary
The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …
|
|
|
|
|
Upcoming eNewsletter Features:
March 29 – Prefilled Syringes
April 5 – Inhalation Drug Delivery
|
|
|
|
|
|
|
|